Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, Susan; Kelly, William Kevin; Ma, Hongwei; Zhou, Haojin; Solomon, Nicole; Fizazi, Karim; Tangen, Catherine M.; Rosenthal, Mark; Petrylak, Daniel P.; Hussain, Maha; Vogelzang, Nicholas J.; Thompson, Ian M.; N., Kim; Bono, Johann S. de; Armstrong, Andrew J.; Eisenberger, Mario A.; Fandi, Abderrahim; Li, Shaoyi; Araujo, John C.; Logothetis, Christopher J.; Quinn, David I.; Morris, Michael J.; Higano, Celestia S.; Tannock, Ian F.; Small, Eric J.

doi:10.1200/jco.2015.65.7270

Cited by 342 publications

(272 citation statements)

References 24 publications

Supporting

Mentioning

258

Contrasting

Unclassified

Order By: Relevance

“…13 In addition, a recent meta-analysis evaluating the impact of site of metastasis on overall survival in men with CRPC showed that liver metastasis predicted worse OS compared to bone metastasis and lymph node only metastasis (13.5 vs 21.3 vs 31.6 months, respectively). 14 In addition to OS, we observed that the 6-factor prognostic index model is predictive of time to PSA progression, PSA response and time on treatment in chemotherapy-naïve patients treated with abiraterone. The use of PSA parameters as a surrogate endpoint for OS in CRPC has generated considerable discussion and controversy.…”

Section: Cuaj -Original Research Khalaf Et Al Stratifying Clinical Oumentioning

confidence: 70%

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Khalaf

Avilés²,

Azad³

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: Recently, a prognostic index including six risk factors (RFs) (unfavourable ECOG performance status [PS], presence of liver metastases, short response to luteinizing hormonereleasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase [ALP] and lactate dehydrogenase [LDH]) was developed from the COU-AA-301 trial in postchemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate. Our primary objective was to evaluate this model in a cohort of chemotherapy-naive mCRPC patients receiving abiraterone. Methods: We identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ 2 test and log-

show abstract

Section: Cuaj -Original Research Khalaf Et Al Stratifying Clinical Oumentioning

confidence: 70%

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Khalaf

Avilés²,

Azad³

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…All of these three were sclerotic lesions, SUVmax range was 1.06-1.08 and PSA value was 3.6-240 (Table 2). The skeleton is the second most frequent site (after lymph nodes) for metastases from prostate cancer, and the incidence of skeletal involvement is 65-75% among patients with advanced disease [9] . Among the 15% of patients with bone lesions in this study, were avid on bone scan (23.1%) while the majority (76.9%) were non-avid.…”

Section: Resultsmentioning

confidence: 99%

Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer

Haroon

Syed

Endozo

et al. 2017

Nuclear Medicine Communications

View full text Add to dashboard Cite

The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase 18 Ffluoroethylcholine (FECH) PET/CT performed during the work-up of patients referred for suspected prostate cancer relapse. Tc-MDP planar bone scans and serum PSA. SUVmax for all except one benign lesion ranged from 0.49 to 2.15. In 51 lesions (71%) due to metastatic disease, SUVmax was 0.6-11.6 for those classified as sclerotic on lowdose CT, 0.7-8.58 for lytic lesions, 1.1-7.65 for isodense lesions, and 1.27-3.53 for mixed lytic/sclerotic lesions. Of the 56 18 F-FECH avid lesions, 21 lesions showed avidity on bone scan {3 (23%) of the 13 isodense lesions, 14 (40%) of the 35 3 sclerotic lesions, 2 (50%) of the lytic lesions, and 2 (50%) of the mixed sclerotic/lytic lesions}. . Methods Conclusion:18 F-FECH PET/CT identified bone lesions in 15% of patients with suspected prostate cancer relapse. SUVmax in isolation cannot be used to characterize these lesions as benign or malignant. Minimal overlap of benign and malignant lesions was seen above SUVmax of 2.5. Low-dose CT of PET/CT is a useful tool to assist characterization.

show abstract

“…Halabi et al reported a ratio of 1.4 between patients with bone metastases only and those with bone plus lymph node metastases (78).…”

Section: Prognostic Factorsmentioning

confidence: 99%

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Buroni

Persico

Pasi

et al. 2016

View full text Add to dashboard Cite

Abstract. 223 Prostate cancer (PCa) is the most common malignancy in men (1). In patients affected by advanced PCa, defined as hormonesensitive disease since the tumor still requires androgen for growth, androgen deprivation therapy (ADT), including luteinizing hormone-releasing hormone (LHRH) agonists, antagonists and anti-androgens, represents the first-line treatment. Unfortunately some cancer cells develop resistance to ADT, indicating the progression of the disease to metastatic castration-resistant prostate cancer (mCRPCa). Such resistance to castration occurs in most patients (2) and, despite the approval of new therapeutic agents, mCRPCa remains a lethal disease (3). Nowadays the new therapeutic landscape for patients affected by mCRPCa aims to extend overall survival (OS) and includes cytotoxic, new-generation anti-androgens, immunotherapeutics and radiopharmaceuticals (4, 5).Bones are the preferred site of metastasis. Almost 90% of men who die from PCa have bone-metastatic disease (6), with a 5-year OS rate of 20%. Due to the fragility of bone with metastases, with the related risk of pain, fractures, spinal cord compression and hematological consequences, several drugs have been developed to treat the osseous involvement of this disease. In previous years, the optimal treatment aimed to relieve pain and reduce skeletal morbidity.Besides systemic therapies, bone-targeted agents that focus their activity on bone, such as bisphosphonates, monoclonal antibody and radiopharmaceuticals, have become available. The bisphosphonate zoledronic acid, the antibody to receptor activator of nuclear factor kappa-B ligand (RANKL) denosumab and radiopharmaceuticals [such as 89 Sr and 153 Sm-ethylene diamine tetramethylene phosphonate ( 153 Sm-EDTMP)], were approved for delaying skeletal-related events (SREs) and for the palliation of bone pain from mCRPCa. Radionuclide TherapyRadionuclide therapy is known to deliver ionizing radiation to tumor sites, thereby killing cancer cells (7). Bone-targeted radiopharmaceuticals localize their radiation to sites of high bone remodeling. 5719

show abstract

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Cited by 342 publications

References 24 publications

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Contact Info

Product

Resources

About